Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
This book presents state-of-the-art knowledge regarding fluid and imaging biomarkers of neurodegenerative disorders, including Alzheimer disease and related dementias (ADRD). A cadre of the top experts in the field discuss the diagnostic and prognostic value of established and emerging biomarkers in ADRD, their ability to track or monitor disease progression or predict cognitive outcomes, and their potential as novel therapeutic targets. Biomarkers are discussed both in the context of specific disease mechanisms, including amyloid, tau, and synuclein pathologies, endothelial, vascular, neuronal, and synaptic injury, and glial reactivity as well as a wide spectrum of neurodegenerative disorders that encompass various pathologies. Multi-omics approaches in ADRD biomarker and drug target discovery including proteomics, genomics, and transcriptomics are covered. Importantly, the authors highlight the need to integrate biomarkers into various stages of ADRD drug development to accelerate drug discovery and approval. The book provides in-depth insight regarding significant progress in ADRD biomarker research over the last decade, addresses potential challenges in the translation of ADRD biomarkers into the clinic, and proposes important directions for future research.
Rawan Tarawneh, MD is Associate Professor of Neurology and Director of the Cognitive Neurology Division at the University of New Mexico. She is a board-certified neurologist with UCNS- certification in Behavioral Neurology and Neuropsychiatry. Dr Tarawneh completed her neurology residency and a combined clinical and post-doctoral research fellowship at the Knight-Washington University in St Louis Alzheimer Disease Research Center. Her NIH-funded research utilizes state-of-the-art proteomic and genomic methods to identify novel biomarkers and drug targets for Alzheimer disease and related dementias. Dr Tarawneh's pioneering work has been fundamental in identifying visinin-like protein-1, neurogranin, and vascular endothelial-cadherin as novel markers of neuronal, synaptic, and endothelial injury, respectively, in AD. As a national leader in ADRD biomarker research, Dr Tarawneh has led several clinical trials in aging and dementia. Her highly cited research in ADRD biomarkers has been published in prestigious journals and featured in national and international conferences.
Section 1: Fluid and Imaging Markers of Pathologies associated with Alzheimer Disease or other Related Dementias.- Chapter 1: Fluid and Imaging Markers of Amyloid Pathology.- Chapter 2: Fluid Markers of Tau Pathology.- Chapter 3: Fluid and Imaging Markers of Synuclein Pathology.- Chapter 4: Fluid and Imaging Markers of Synaptic Injury.- Chapter 5: Fluid Markers of Neuronal and Axonal Injury.- Chapter 6: Fluid and Imaging Markers of Glial Reactivity.- Chapter 7: Fluid and Imaging Markers of Vascular Disease.- Section 2: Fluid and Imaging Markers of Neurodegenerative Disorders.- Chapter 8: Fluid and Imaging Markers of Alzheimer Disease.- Chapter 9: Fluid and Imaging Markers of Frontotemporal Lobar Degeneration.- Chapter 10: Fluid and Imaging Markers of Lewy body dementias.- Chapter 11: Fluid and Imaging Markers of Huntington's Disease.- Section 3: Single and Integrated Omics Studies in Biomarker Discovery.- Chapter 12: Proteomics for Novel Biomarker and Drug Target Discovery in Alzheimer Disease.- Chapter 13: Genomics and Transcriptomics of Alzheimer Disease.- Section 4: Biomarkers in Clinical and Translational Alzheimer Disease Research.- Chapter 14: Biomarkers in Clinical Trials of Alzheimer Disease: An Overview.- Chapter 15: Biomarkers As Outcome Measures in Clinical Trials of Alzheimer Disease.- Chapter 16: Impact of Pre-analytical Factors on Fluid Biomarker Measurements in Alzheimer Disease.- Chapter 17: Mild Behavioral Impairment and Alzheimer's Disease Biomarker Sample Enrichment for Clinical Trial Screening and Recruitment.- Section 5: Future Directions in Biomarker Research.- Chapter 18: Extracellular Vesicles as Biomarkers in Alzheimer Disease and Related Dementias.- Chapter 19: Sex Differences in Alzheimer Disease-Related Biomarkers and Dementia Risk.- Chapter 20: Imaging Markers of Amyloid and Tau.- Chapter 21: Novel Markers of Brain Endothelial Injury.- Epilogue: Expert Commentary on Future Directions or Epilogue: Sex/racial differences, standardization, and TDP-43.
Dateiformat: PDFKopierschutz: Wasserzeichen-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Wasserzeichen-DRM wird hier ein „weicher” Kopierschutz verwendet. Daher ist technisch zwar alles möglich – sogar eine unzulässige Weitergabe. Aber an sichtbaren und unsichtbaren Stellen wird der Käufer des E-Books als Wasserzeichen hinterlegt, sodass im Falle eines Missbrauchs die Spur zurückverfolgt werden kann.
Weitere Informationen finden Sie in unserer E-Book Hilfe.
